New Hampshire
Prescription drug spending and prescribing in New Hampshire, from Medicare Part D and Medicaid, with the life-science companies raising money there and state attorney general health-care antitrust cases. Compare every state.
In 2024, Medicare Part D plans paid $1.1B for prescriptions written in New Hampshire, the 42nd most of 52 states and territories, and 3.0% of its claims were opioids against 3.5% nationally.
- Medicare Part D, 2024: $1.1B
- Medicaid drugs, 2025: $272M
- Opioid share of claims: 3.0%
- Life-science raises, 2 years: $47M
Opioid share of Part D claims, 2024
New Hampshire outlined; every state in quartiles. Click a state to compare.
- Up to 3.2%
- 3.2% to 3.7%
- 3.7% to 4.3%
- Over 4.3%
| Share of Part D claims | New Hampshire | United States | Difference |
|---|---|---|---|
| Opioids | 3.0% | 3.5% | −16% |
| Antibiotics | 4.4% | 4.4% | −1% |
| Antipsychotics | 2.3% | 1.7% | +29% |
| Drug | Against national rate | Claims |
|---|---|---|
| Buprenorphine HCl | 3.4× | 8,188 |
| Methylphenidate HCl | 3.3× | 12,558 |
| Buprenorphine HCl/naloxone HCl | 3.3× | 24,860 |
| Lisdexamfetamine dimesylate | 3.0× | 5,066 |
| Cefpodoxime proxetil | 2.7× | 5,923 |
| Dextroamphetamine/amphetamine | 2.7× | 27,932 |
| Naltrexone HCl | 2.5× | 4,700 |
| Clozapine | 2.2× | 10,772 |
| Hydromorphone HCl | 2.2× | 7,152 |
| Lorazepam | 2.2× | 72,782 |
- Conformal Medical, Inc.$32M · Other health care · Aug 13, 2025
- Beckley Clinical, P.B.C.$7.4M · Other health care · Jun 2, 2026
- Project Belle LLC$2.8M · Other health care · Mar 26, 2026
- PIROUETTE PHARMA INC.$2.4M · Pharma · Apr 1, 2025
- PIROUETTE PHARMA INC.$1.1M · Pharma · Mar 18, 2026
- PRC Enterprises LLC$950K · Other health care · Mar 13, 2026
- Assurtek Surgical, Inc.$370K · Biotech · Nov 25, 2024
- Patriot Pay, LLC$275K · Other health care · Feb 18, 2026
- Lodestone Biomedical, Inc.$75K · Biotech · Jul 9, 2025
- nira innovations Inc$25K · Biotech · May 1, 2026
- Connecticut, et al. v. Sandoz, et al., Case No. 20-cv-3539 (E.D. Pa. June 10, 2020), MDL 2724 (E.D. Pa.)2020 · Pending
- State of Wisconsin et al. v. Indivior, No. 16-5073 (E.D. Pa. Sept. 22,2016)2016 · Pending
- New York et al. v. Cephalon, No. 2:16-cv-04234 (E.D. Pa. Aug. 4, 2016)2016 · Settled
- Maryland v. SmithKline Beecham Corp., No. 2:06-cv-01298-JP (E.D.Pa Mar. 27, 2006)2006 · Settled
- Maryland et al. v. Perrigo Company, No. 1:04CV01398 (D.D.C. Aug. 17, 2004)2004 · Settled
- Texas et al. v. Organon (Remeron), No. 04-5126 (D.N.J. 2004)2004 · Settled
- In re Cardizem CD Antitrust Litigation 99-MD-1278 (E.D. Mich. Jan. 29, 2003), 332 F.3d 896 (6th Cir. 2003)2003 · Settled
- Ohio, et al, v. Bristol-Myers Squibb Co., et al.(D.D.C. 2002); see also In re Buspirone Antitrust Litigation,Case No.…2002 · Settled
- In re Clozapine Antitrust Litigation, MDL No. 874 (N.D. Ill. 1991)1991 · Settled
- In the Matter of GlaxoSmithKline, PLC (Augmentin)Settled
Alabama · Alaska · Arizona · Arkansas · California · Colorado · Connecticut · Delaware · District of Columbia · Florida · Georgia · Hawaii · Idaho · Illinois · Indiana · Iowa · Kansas · Kentucky · Louisiana · Maine · Maryland · Massachusetts · Michigan · Minnesota · Mississippi · Missouri · Montana · Nebraska · Nevada · New Jersey · New Mexico · New York · North Carolina · North Dakota · Ohio · Oklahoma · Oregon · Pennsylvania · Puerto Rico · Rhode Island · South Carolina · South Dakota · Tennessee · Texas · Utah · Vermont · Virginia · Washington · West Virginia · Wisconsin · Wyoming
Part D is by the prescriber's state, Medicaid by the paying state program, and Form D by the issuer's stated address. Amounts are before manufacturer rebates. Refreshed weekly. CMS Medicare Part D Prescribers by Geography; CMS State Drug Utilization Data; SEC Form D; NAAG